Last reviewed · How we verify
PCRA (Intermittent injection)
PCRA is a peptide-based immunotherapeutic that stimulates the patient's own immune system to recognize and attack cancer cells.
PCRA is a peptide-based immunotherapeutic that stimulates the patient's own immune system to recognize and attack cancer cells. Used for Colorectal cancer (marketed indication).
At a glance
| Generic name | PCRA (Intermittent injection) |
|---|---|
| Sponsor | Örebro University, Sweden |
| Drug class | Cancer vaccine / Autologous cell therapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
PCRA (Personalized Cancer Vaccine) is designed as an autologous cell-based immunotherapy that primes T-cell responses against tumor-associated antigens. Administered as intermittent injections, it aims to enhance anti-tumor immunity by activating dendritic cells and cytotoxic T lymphocytes. The exact molecular targets and antigen specificity are proprietary to Örebro University's development.
Approved indications
- Colorectal cancer (marketed indication)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- A Comparison Between Continuous and Intermittent Intraabdominal Analgesia Using Local Anaesthetics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |